Atenolol: Difference between revisions
Elcatracho (talk | contribs) |
|||
| (30 intermediate revisions by 7 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Beta blocker]] | *Type: [[Beta blocker]] | ||
*Dosage Forms: | *Dosage Forms: tablet | ||
*Common Trade Names: | *Dosage Strengths: 25, 50, 100mg | ||
*Routes of Administration: PO | |||
*Common Trade Names: Tenormin | |||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Hypertension]]=== | |||
*50-100mg PO QD, Start 50mg PO QD | |||
*Max: 100mg/day | |||
===[[Stable angina]]=== | |||
*50-200mg PO QD, Start 50mg PO QD | |||
*Max: 200mg/day | |||
===Cardiovascular event prevention, post-MI=== | |||
*100mg/day PO divided QD-bid | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Hypertension]]=== | |||
*1-2mg/kg PO QD, Start 0.8-1mg/kg PO QD | |||
*Max: 2mg/kg/day | |||
===[[Supraventricular arrhythmias]]=== | |||
*0.3-2mg/kg PO QD | |||
*Max: 2mg/kg/day | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: D | ||
*Lactation: | *Lactation: Possibly unsafe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCl 10-50: decrease dose 50%, give q48h, max 50mg/day; CrCl<10: decrease dose 50-70%, give q96h, max 25mg/day; HD: give dose after dialysis, no supplement; PD: no supplement | ||
**Pediatric | **Pediatric: CrCl 30-50: max 1mg/kg up to 50mg q24h; CrCl<30: max 1mg/kg up to 25mg q24h or up to 50mg q48h; HD: give dose after dialysis, no supplement; PD: no supplement | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: not defined | ||
**Pediatric | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*sinus bradycardia | |||
*2nd or 3rd degree AV block | |||
*heart failure, uncompensated | |||
*cardiogenic shock | |||
*sick sinus syndrome with out pacemaker | |||
*pheochromocytoma, untreated | |||
*avoid abrupt withdrawal | |||
*caution if peripheral vascular disease | |||
*caution if bronchospastic disease | |||
*caution if major surgery | |||
*caution if diabetes mellitus | |||
*caution if thyroid disorder | |||
*caution if WPW syndrome | |||
*caution if renal impairment | |||
*caution if pregnancy | |||
*caution if breastfeeding | |||
*caution if myasthenia gravis | |||
*caution if severe anaphylactic reaction history | |||
*caution in elderly patients | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[CHF]] | |||
*[[bradycardia]], severe | |||
*heart block | |||
*angina exacerbation if abrupt discontinuation | |||
*[[Myocardial infarction]] if abrupt discontinuation | |||
*ventricular arrhythmia during treatment and if abruptly discontinue | |||
*Raynaud phenomenon | |||
*bronchospasm | |||
*hypersensitivity reaction | |||
*lupus erythematosus | |||
===Common=== | ===Common=== | ||
*bradycardia | |||
*hypotension | |||
*fatigue | |||
*dizziness | |||
*cold extremities | |||
*depression | |||
*dyspnea | |||
*hypotension, orthostatic | |||
*leg pain | |||
*bronchospasm | |||
*lightheadedness | |||
*lethargy | |||
*diarrhea | |||
*nausea | |||
*vertigo | |||
*drowsiness | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 33: | Line 97: | ||
==See Also== | ==See Also== | ||
*[[Beta-blockers]] | |||
*[[Beta-blocker toxicity]] | |||
*[[Antiarrhythmics]] | |||
*[[Antihypertensive medications]] | |||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] [[Category:Cardiology]] | |||
[[Category: | |||
Latest revision as of 01:23, 7 March 2021
General
- Type: Beta blocker
- Dosage Forms: tablet
- Dosage Strengths: 25, 50, 100mg
- Routes of Administration: PO
- Common Trade Names: Tenormin
Adult Dosing
Hypertension
- 50-100mg PO QD, Start 50mg PO QD
- Max: 100mg/day
Stable angina
- 50-200mg PO QD, Start 50mg PO QD
- Max: 200mg/day
Cardiovascular event prevention, post-MI
- 100mg/day PO divided QD-bid
Pediatric Dosing
Hypertension
- 1-2mg/kg PO QD, Start 0.8-1mg/kg PO QD
- Max: 2mg/kg/day
Supraventricular arrhythmias
- 0.3-2mg/kg PO QD
- Max: 2mg/kg/day
Special Populations
- Pregnancy Rating: D
- Lactation: Possibly unsafe
- Renal Dosing
- Adult: CrCl 10-50: decrease dose 50%, give q48h, max 50mg/day; CrCl<10: decrease dose 50-70%, give q96h, max 25mg/day; HD: give dose after dialysis, no supplement; PD: no supplement
- Pediatric: CrCl 30-50: max 1mg/kg up to 50mg q24h; CrCl<30: max 1mg/kg up to 25mg q24h or up to 50mg q48h; HD: give dose after dialysis, no supplement; PD: no supplement
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- sinus bradycardia
- 2nd or 3rd degree AV block
- heart failure, uncompensated
- cardiogenic shock
- sick sinus syndrome with out pacemaker
- pheochromocytoma, untreated
- avoid abrupt withdrawal
- caution if peripheral vascular disease
- caution if bronchospastic disease
- caution if major surgery
- caution if diabetes mellitus
- caution if thyroid disorder
- caution if WPW syndrome
- caution if renal impairment
- caution if pregnancy
- caution if breastfeeding
- caution if myasthenia gravis
- caution if severe anaphylactic reaction history
- caution in elderly patients
Adverse Reactions
Serious
- CHF
- bradycardia, severe
- heart block
- angina exacerbation if abrupt discontinuation
- Myocardial infarction if abrupt discontinuation
- ventricular arrhythmia during treatment and if abruptly discontinue
- Raynaud phenomenon
- bronchospasm
- hypersensitivity reaction
- lupus erythematosus
Common
- bradycardia
- hypotension
- fatigue
- dizziness
- cold extremities
- depression
- dyspnea
- hypotension, orthostatic
- leg pain
- bronchospasm
- lightheadedness
- lethargy
- diarrhea
- nausea
- vertigo
- drowsiness
Pharmacology
- Half-life: 6-7h
- Metabolism: CYP450
- Excretion: urine 40-50%, feces 50%
- Mechanism of Action: selectively antagonizes beta-1 adrenergic receptors